Welcome to
Sysmex Flow Cytometry Belgium!

For ordering please make sure you are in your local shop.
If you are from Belgium then please continue.
Otherwise please go to your country.

Go to my country Continue

Article successfully added.

CyFlow™ CD19 Purified

CyFlow™ CD19 Purified
Antigen: CD19
Alternative Name: B4
Clone: LT19
Application: Flow cytometry, Immunoprecipitation
Format/Fluorochrome: Purified
Target Species: Human
Field of Interest: Immunophenotyping
Species of Origin: Mouse
Regulatory Status: RUO
Clonality: monoclonal
Isotype: IgG1
Order number: CA166767

For Research Use Only
Not for use in diagnostic or therapeutic procedures.

HLDA Workshop HLDA 10 Concentration Unit mg/mL Concentration 1 Quantity 0.1 mg... more
CyFlow™ CD19 Purified
HLDA WorkshopHLDA 10
Concentration Unitmg/mL
Concentration1
Quantity0.1 mg
Volume0.1
ImmunogenDaudi human Burkitt lymphoma cell line
Background InformationCD19 is a transmembrane glycoprotein of Ig superfamily expressed by B cells from the time of heavy chain rearrangement until plasma cell differentiation. It forms a tetrameric complex with CD21 (complement receptor type 2), CD81 (TAPA-1) and Leu13. Together with BCR (B cell antigen receptor), this complex signals to decrease B cell treshold for activation by the antigen. Besides being signal-amplifying coreceptor for BCR, CD19 can also signal independently of BCR coligation and it turns out to be a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src‑family protein tyrosine kinase activation. J·Immunol. 1999·Jun·15; 162(12):7088‑94. <·PMID:·10358152·> | Inabe K, Kurosaki T: Tyrosine phosphorylation of B‑cell adaptor for phosphoinositide 3‑kinase is required for Akt activation in response to CD19 engagement. Blood. 2002·Jan·15; 99(2):584‑9. <·PMID:·11781242·> | Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM: Strong cytosine‑guanosine‑independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J·Immunol. 2003·Oct·1; 171(7):3697‑704. <·PMID:·14500668·> | Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood. 2005·Nov·15; 106(10):3567‑74. <·PMID:·16046525·> | van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody‑deficiency syndrome due to mutations in the CD19 gene. N·Engl·J·Med. 2006·May·4; 354(18):1901‑12. <·PMID:·16672701·> | Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1‑induced humoral autoimmunity but not clinical nephritis. Arthritis·Rheum. 2007·Sep; 56(9):3057‑69. <·PMID:·17763445·> | Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M: Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8‑color flow cytometry protocol in routine hematological practice. Int·J·Lab·Hematol. 2014·Apr; 36(2):165‑71. <·PMID:·24028768·>